ReviewInternational journal of molecular sciences2022
Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- All-cause and cause-specific mortality in psoriasis patients: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Keratinocyte-specific STAT3 knockout attenuates imiquimod-induced psoriasiform phenotype in mice.Experimental animals · 2026Article
- Molybdenum Nanoparticles Alleviate Psoriasis-Related Cardiovascular Oxidative Stress and Inflammation.ACS omega · 2026Article
- Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction: Literature Review and (Early) Economic Assessment.Dermatology and therapy · 2026Review
- Joint Relationship of Cardiovascular-kidney-metabolic Syndrome and Psoriasis with All-cause and Cause-specific Mortality in Adults: A Population-based Analysis.Acta dermato-venereologica · 2026Article
- Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.International journal of molecular sciences · 2026Review
- Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.Dermatology and therapy · 2026Article
- Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.Inflammopharmacology · 2026Review
- The Heart of Psoriasis: Cardiovascular Alterations and Common Inflammatory Mechanisms.Current cardiology reviews · 2026Review
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards.Frontiers in immunology · 2026Article
- Bidirectional Inflammatory Mechanisms and Hematological/Coagulation Dysregulation in Psoriasis Complicated with Atherosclerosis: A Retrospective Hospital-Based Case-Control Study Leveraging the SH-YIMED Clinical Database.Psoriasis (Auckland, N.Z.) · 2026Article
- Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications.Frontiers in immunology · 2026Review
- Evaluating the Body Roundness Index as a Novel Digital Biomarker for Psoriasis Risk Prediction: Cross-Sectional Study.JMIR medical informatics · 2025Article
- Cardiometabolic Candidate Endotypes in Psoriatic Disease: Integration of Clinical, Metabolic, and Immunogenetic Data Across Psoriasis and Psoriatic Arthritis.Life (Basel, Switzerland) · 2025Article
- Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways.Scientific reports · 2025Article
- Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.World journal of clinical cases · 2025Article
- The co-impact of diabetes and psoriasis on mortality risk for all causes and specific causes.Scientific reports · 2025Article
- A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.Health science reports · 2025Article
- Association of skin microbiome with interleukin-23 in patients with plaque psoriasis.Postepy dermatologii i alergologii · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A convincing deal of evidence supports the fact that severe psoriasis is associated with cardiovascular diseases. However, the precise underlying mechanisms linking psoriasis and cardiovascular diseases are not well defined. Psoriasis shares common pathophysiologic mechanisms with atherosclerosis and cardiovascular (CV) risk factors. In particular, polymorphism in the IL-23R and IL-23 genes, as well as other genes involved in lipid and fatty-acid metabolism, renin-angiotensin system and endothelial function, have been described in patients with psoriasis and with cardiovascular risk factors. Moreover, systemic inflammation in patients with psoriasis, including elevated serum proinflammatory cytokines (e.g., TNF-α, IL-17, and IL-23) may contribute to an increased risk of atherosclerosis, hypertension, alteration of serum lipid composition, and insulin resistance. The nonlinear and intricate interplay among various factors, impacting the molecular pathways in different cell types, probably contributes to the development of psoriasis and cardiovascular disease (CVD). Future research should, therefore, aim to fully unravel shared and differential molecular pathways underpinning the association between psoriasis and CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.